-
Breaking News! Chia Tai Tianqing to Receive Approval for another Generic in China
Industry Data
CaicaiMarch 26, 2021
The marketing application (acceptance No.: CYHS1900381) of Chia Tai Tianqing’s Class 4 generic drug has recently changed to the “Under approval” status, and the drug is expected to be approved for marketing this month ...
-
A Review of the Export Data of China’s Plant Extract Market in 2020 and Potential Varieties
Industry Data
PharmaSources.comMarch 18, 2021
In 2020, the outbreak of the pandemic stimulated consumer demand for naturally sourced plant extracts, however, China’s export value of plant extracts in the first half of 2020 reached USD1.265 billion, up only 1.08% year on year.
-
Plant Extract Varieties with Great Market Potential
Industry Data
PharmaSources.comMarch 12, 2021
The following plant extract varieties is considered to have great potential after summarizing various buying information and the sales of plant extracts in the U.S. market last year.
-
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020
Industry Data
CaicaiMarch 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
-
Advantages to Drug Companies to Approach Continuous Manufacturing
Industry Data
Deepak HegdeMarch 11, 2021
Learning what are the features attracting big pharma and generic companies to approach Continuous Manufacturing process from Batch Manufacturing process by reading Dr. Deepak Hegde's Continuous Manufacturing series articles.
-
Neutralizing Antibodies, the “Specific Drugs” against SARS-CoV-2
Industry Data
YefenghongMarch 04, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic and become a serious public health and socioeconomic burden, and thus there is an urgent need for effective means of control.
-
Qilu Pharmaceutical Achieved Staggering Sales of Bevacizumab of RMB1.8 Billion in 2020
Industry Data
CaicaiMarch 04, 2021
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.
-
Analysis of the Export Market of Gelatin and Its Derivatives
Industry Data
Chen ShipengFebruary 19, 2021
Gelatin is a product made from animal bones, skins, muscles, tendons and scales after moderate hydrolysis (acid process, alkaline process, acid/alkaline process or enzymic method) and purification.
-
Enzymatic Synthesis of NMN: Greener and More Efficient
Industry Data
YuntianFebruary 19, 2021
NMN, i.e., nicotinamide mononucleotide (Fig. 1), is a reaction product of nicotinamide phosphoribosyltransferase (NAMPT).
-
A Review of Chinese-produced Class 1 New Drugs from 2018 to 2020
Industry Data
CaicaiJanuary 28, 2021
From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic.
The marketing application (acceptance No.: CYHS1900381) of Chia Tai Tianqing’s Class 4 generic drug has recently changed to the “Under approval” status, and the drug is expected to be approved for marketing this month ...
In 2020, the outbreak of the pandemic stimulated consumer demand for naturally sourced plant extracts, however, China’s export value of plant extracts in the first half of 2020 reached USD1.265 billion, up only 1.08% year on year.
The following plant extract varieties is considered to have great potential after summarizing various buying information and the sales of plant extracts in the U.S. market last year.
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
Learning what are the features attracting big pharma and generic companies to approach Continuous Manufacturing process from Batch Manufacturing process by reading Dr. Deepak Hegde's Continuous Manufacturing series articles.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic and become a serious public health and socioeconomic burden, and thus there is an urgent need for effective means of control.
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.
Gelatin is a product made from animal bones, skins, muscles, tendons and scales after moderate hydrolysis (acid process, alkaline process, acid/alkaline process or enzymic method) and purification.
NMN, i.e., nicotinamide mononucleotide (Fig. 1), is a reaction product of nicotinamide phosphoribosyltransferase (NAMPT).
From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic.
Pharma Sources Insight 01/2021